Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
78.330.00 (0.00%)
At close: 4:02PM EDT
78.48 +0.15 (+0.19%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close78.33
Open78.20
Bid78.33 x 1200
Ask78.43 x 1100
Day's Range77.98 - 79.06
52 Week Range68.44 - 84.56
Volume11,762,580
Avg. Volume13,244,548
Market Cap198.282B
Beta (5Y Monthly)0.42
PE Ratio (TTM)35.67
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.60 (3.32%)
Ex-Dividend DateSep 14, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-15% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MRK

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Merck & Company, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the continuing shift to software; biopharma capital allocation; rising ransomware attacks; and new coverage of Stem, Keysight, and Carlyle Group.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Reuters

    Merck COVID-19 pill sparks calls for access for lower income countries

    The plan to roll out Merck & Co's promising antiviral pill to treat COVID-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with the greatest need once again at the back of the line, international health groups say. Merck on Oct 11 applied for U.S. emergency clearance of the first pill for COVID-19 after it cut hospitalizations and deaths by 50% in a large clinical trial. The medicine, made with Ridgeback Biotherapeutics, could gain authorization as soon as December.

  • Motley Fool

    3 COVID-19 Pill Stocks to Watch

    Merck (NYSE: MRK) and Ridgeback Biotherapeutics have already made a big splash with positive results for their COVID-19 pill. However, there are are other companies nipping at their heels. In this Motley Fool Live video recorded on Oct.

  • Motley Fool

    Better COVID-19 Stock: Merck or Pfizer?

    Pfizer (NYSE: PFE) launched the best-selling vaccine Comirnaty with the help of its partner, BioNTech. Merck (NYSE: MRK) is likely to soon have the first COVID-19 pill on the market. Pfizer has delivered greater stock gains than Merck since the beginning of the pandemic.

Advertisement
Advertisement